Dr. Herbert Loong’s highlights from ESMO24

24th European Society for Medical Oncology (ESMO) Congress, a major event in the field of oncology. ESMO24 typically features presentations on the latest research, treatment advancements, and clinical practices in oncology.

It gathers experts from around the world to discuss cutting-edge developments in cancer treatment, including new therapies, clinical trials, and advancements in personalized medicine. ESMO 2024 will take place in Barcelona, Spain from 13-17 September this year. In connection to that, Herbert Loong shared several valuable posts from ESMO24 on her X account:

Thrilled to have Silvia Stacchiotti

“Thrilled to have Silvia Stacchiotti walk us through landmark bone and joint sarcoma trials including TGCT during the ESMO24 sarcoma educational session.”

Hottopics In Sarcomas

“Kicking off the 1st session of Hottopics In Sarcomas ESMO24 is Dr. Emine Hatipoglu of  ICR The Royal Marsden NHS Foundation Trust
taking us a on landmark soft tissue sarcoma trials. Lots done but still lots id unanswered questions for us to work on.”

Immunotherapy trials in sarcomas

“Next up we have sarcoma immunotherapy Breelyn Wilky rockstar taking us on a tour of landmark immunotherapy trials in sarcomas. Checkpoint inhibitors are only the beginning, the answer is in checkpointPlus and cellular-therapies.”

GIST guru

“The final speaker of sarcoma ed session is GIST guru seppobauer taking us through the earlier and contemporary clinical trials of primary GISTs and strategies to deal with diseaseresistance. Lessons learned from failed early nilotinib trial before attempting to dethrone imatinib with novel agents!”

Bumped into you Thierry Alcindor

It’s always wonderful to bump into sarcoma peeps in the corridors of ESMO24! Great to have bumped into you Thierry Alcindor!

CDK4 inhibitor Plus approach

“Excellent presentations by Drs. Brahmi and Dr. Rosenbaum on addressing DDLPS with a CDK4 inhibitor Plus approach – either combo with a MDM2inhibitor or a checkpoint inhibitor. Promising approach for this difficult disease. Will need appropriate comparator to move forward.”

AXAGIST study

“Congrats Piotr Rutkowski and team for presenting their investigator initiated AXAGIST study on axitinib and avelumab in refractory GISTs. Disease control rate of up to 70% in this hard to treat group!”

Dr. Herbert H. F. Loong holds several prominent positions in oncology. He is the Chair-Elect of the International Affairs Committee, a Scientific Track Member (2022-2024), and the Track Leader for Sarcoma (2023) at the American Society of Clinical Oncology (ASCO). Additionally, he has been promoted to Steering Committee Member at the Lung Cancer Policy Network.

Dr. Loong is also the Chairperson of the Asia Pacific Coalition against Lung Cancer, a Board Member of the Connective Tissue Oncology Society, and a Committee Member of the International Association for the Study of Lung Cancer. He is an Associate Professor in the Department of Clinical Oncology at The Chinese University of Hong Kong (CUHK).

Find other posts about ESMO24 on OncoDaily.